Major pharmaceutical companies are significantly expanding their U.S. manufacturing operations, with three industry leaders announcing plans to create over 4,500 new jobs across multiple facilities. The expansion reflects growing investment in domestic production capabilities as companies strengthen their manufacturing infrastructure.
Eli Lilly Leads Manufacturing Expansion
Eli Lilly expects to add over 3,000 positions for highly skilled workers across four new manufacturing sites whose locations will be announced later this year. The company currently has nearly 275 manufacturing jobs available across various locations, including senior principal scientist/advisor positions for MES-Lebanon API manufacturing in Lebanon, Indiana, and HVAC engineer roles at the Lilly Medicine Foundry in Indianapolis.
Johnson & Johnson and Novartis Scale Operations
Johnson & Johnson is creating over 500 jobs at its Wilson, North Carolina facility that broke ground in March. Meanwhile, Novartis will add nearly 1,000 positions at 10 facilities that are part of its recently announced investment in research and development and manufacturing. Nine of those locations represent new or expanded manufacturing sites.
Widespread Industry Hiring Activity
The manufacturing expansion extends beyond the three major announcements, with numerous pharmaceutical and biotechnology companies actively recruiting manufacturing professionals. Companies including AbbVie, Amgen, BioMarin, CSL, Insmed, Novo Nordisk, Regeneron, Resilience, and Takeda have collectively posted hundreds of manufacturing positions across various specialties.
Available roles span multiple disciplines, from process development scientists and manufacturing engineers to quality assurance specialists and production operators. Positions range from entry-level manufacturing technicians to senior leadership roles, including directors of engineering and facilities operations.
Geographic Distribution of Opportunities
The manufacturing job creation spans multiple states, with significant activity in North Carolina, Indiana, California, New Jersey, and Illinois. Companies are establishing both new facilities and expanding existing operations to meet growing demand for pharmaceutical manufacturing capacity.
The expansion represents a broader trend of pharmaceutical companies investing in U.S. manufacturing infrastructure, driven by supply chain considerations and the need for increased production capacity across various therapeutic areas.
